Physician profile
Hannah Grainger
NPI 1861052565
$1,406.65
in general payments reported to CMS, 2019-2025
16 companies · $467 in 2025
The $467 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $282 · 2022: $73.04 · 2023: $281 · 2024: $303 · 2025: $467.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,036 · Education: $15.25.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,036.11 |
| Education | $15.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $282.25 | 2021 | |
| Sobi, INC | $282.01 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $176.18 | 2024-2025 | Imfinzi |
| Saluda Medical Americas, INC. | $138.53 | 2025 | Evoke |
| Exelixis INC. | $122.85 | 2024-2025 | Cabometyx |
| E.R. Squibb & Sons, L.L.C. | $119.70 | 2023 | Opdivo |
| Novartis Pharmaceuticals Corporation | $58.65 | 2024 | |
| Amgen INC. | $37.99 | 2023 | Vectibix, Xgeva, Nplate |
| Pharmacyclics LLC, An Abbvie Company | $37.36 | 2023 | Imbruvica |
| Acrotech Biopharma INC. | $28.34 | 2024 | Beleodaq |
| Celgene Corporation | $23.21 | 2023 | Reblozyl |
| Blueprint Medicines Corporation | $22.11 | 2024 | Ayvakit |
| Azurity Pharmaceuticals, INC. | $20.78 | 2024 | Vivimusta |
| Bayer Healthcare Pharmaceuticals INC. | $20.48 | 2023 | |
| Pharmacosmos Therapeutics INC. | $18.71 | 2024 | Monoferric |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $17.50 | 2023 | Keytruda |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hannah Grainger listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.